Ichnos Glenmark Innovation’s full dose-escalation data show high response rates of ISB 2001

Merck withdraws Biologics License Application for Patritumab Deruxtecan

The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance

Zydus Lifesciences completes 25 years of listing on NSE

Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores

Carbogen Amcis Shanghai site receives drug manufacturing license from Chinese NMPA

WHO prequalifies Syngenta’s innovative insecticide Sovrenta

A new weapon in the global fight against malaria

Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s

Raichur site is the group’s largest API facility and part of a wider network of seven sites

Knya forays into medical equipment category with '6sense Stethoscope'

The stethoscope features high acoustic sensitivity and active noise cancellation, minimizing ambient interference to improve auscultation clarity, particularly in noisy hospital settings

Auro Vaccines terminates license agreement with Hilleman Laboratories Singapore

This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials

Pfizer’s BRAFTOVI combination demonstrates improved response for mutant metastatic colorectal cancer

BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation

Synaffix and Mitsubishi Tanabe Pharma ink license agreement for ADC technology

Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement